When the drug fomivirsen was approved by the FDA in 1998 for the treatment of cytomegalovirus retinitis in patients with HIV/AIDs, it was hailed as a milestone in drug discovery because it was the ...

DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/q3z4pf/pharmasphere) has announced the addition of the "PharmaSphere ...

Gene silencing by RNA interference (RNAi) has become a powerful tool for functional genomics. In the January 25 Science, Tijsterman et al. report a gene-silencing method induced by short (25 ...

HOUSTON, Aug. 08, 2024 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ: BPTH) a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a ...

HOUSTON, April 18, 2024 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc. (BPTH), a biotechnology company leveraging its proprietary DNAbilize ® antisense RNAi nanoparticle technology to develop a portfolio ...

Is gene silencing the future of Alzheimer’s disease treatment? Alnylam and Biogen presented first drafts of their answer to that question this week by publishing early-phase data on their respective ...

When Andrew Fire of the Carnegie Institution in Washington, DC, set out to understand some confusing results obtained with antisense RNA in 1998, 1 he could not have known he was firing the opening ...

As people age, it becomes harder to know who is on track for healthy years ahead and who may be at higher risk for serious decline. A new study suggests that part of the answer may already be ...

Ionis is a leader in RNA-based therapies, and its spinal muscular atrophy drug Spinraza, marketed by partner Biogen, is the first RNA-based therapy to achieve blockbuster status. The firm's antisense ...

HOUSTON, March 28, 2025 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc. (BPTH),, a biotechnology company leveraging its proprietary DNAbilize ® antisense RNAi nanoparticle technology to develop a ...

HOUSTON, May 22, 2025 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (OTCQB:BPTH) a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a ...